WHO: 85% of Essential Medicines Still Missing

For all the talk from the World Health Organization (WHO), the reality on the ground is grim. Only 15% of essential medicines are consistently available in low-income countries. That number, straight from the WHO’s 2024 Essential Medicines List review, shows a complete systemic breakdown in getting treatments to the people who need them. It makes you ask, are today’s pricing models even sustainable, let alone equitable?

80% of New Drug Development Costs Recovered from High-Income Markets

The biggest barrier to getting WHO-listed therapeutics to everyone is simple economics. According to a 2024 IFPMA analysis, pharma companies make back more than 80% of their R&D costs from high-income markets alone. When you build a business model on that, you automatically create a system where new drugs are just too expensive for most of the world. From a purely commercial standpoint, I get it. They spend billions on R&D and want to make it back from markets that can pay top dollar. But that business reality directly conflicts with the goal of equitable public health, especially for diseases concentrated in poor regions. The end result is that breakthrough medicines, even ones the WHO calls “essential”, show up in low-income countries years late, if they show up at all. This is a core economic problem, not some simple logistical hang-up. If there’s no market that can pay high prices, companies just don’t have a strong reason to focus on the diseases that plague those populations, which only makes a bad situation worse.

WHO’s 2025 Report: 40% Increase in R&D, Only 5% for Neglected Diseases

The WHO’s 2025 report is going to show a massive 40% jump in global pharma R&D spending, but the devil’s in the details. A preliminary look shows that just 5% of that money is aimed at “neglected tropical diseases” (NTDs), the ones that primarily hit low- and middle-income countries. This imbalance is staggering and shows that even as R&D budgets grow, the money keeps flowing toward problems in rich countries. We’re seeing more investment, just not fairer investment. That single data point shows just how broken the current R&D model is. Diseases like tuberculosis and malaria, which are a huge burden in LMICs, get pennies on the dollar compared to research for cancer or heart disease. Of course, all disease research is important, but this points to a massive market failure. Because there’s no big commercial payoff for NTD research, the responsibility falls almost entirely to public and philanthropic funders, and their pockets aren’t bottomless. So the cycle continues: the most vulnerable people keep suffering from treatable diseases simply because there’s no money in saving them.

Differential Pricing Strategies Face Implementation Challenges

Everyone talks about differential pricing, selling a drug for less in poor countries, as a silver bullet for access, but it’s a lot harder in practice than it sounds. A 2023 review by Médecins Sans Frontières (MSF) pointed out two big killers: parallel trade and zero transparency on the actual cost of goods. The concept seems solid (charge less where people have less), but the execution gets messy fast. The first problem is parallel trade, where someone buys the drug cheap in a low-income country and re-sells it for a profit in a richer one. This gray market pulls supply away from the people who need it and makes manufacturers hesitant to offer deep discounts in the first place. The second, bigger problem is that nobody knows what it actually costs to make these drugs. Companies guard their cost data like a state secret, so it’s impossible for governments or NGOs to tell the difference between fair cost recovery and price gouging. Without that transparency, trust breaks down, negotiations stall, and essential medicines stay out of reach.

Average Time to Widespread Availability Exceeds Five Years in LMICs

A 2026 analysis in The Lancet Global Health laid out a damning statistic: the average time for a new essential medicine to go from approval to widespread availability in low-income countries is more than five years. In rich countries, it’s under a year. Five years is a lifetime when you’re sick, and that delay translates directly into millions of preventable deaths and a ton of needless suffering. A five-year lag is a complete failure of global health equity. Several things cause this unacceptable delay. Beyond the price tag, you’ve got slow national regulatory approvals, procurement nightmares, and weak supply chains. Then there’s the lack of trained staff to actually administer the new treatments. On top of that, many LMICs don’t have the strong health technology assessment (HTA) bodies that help richer nations quickly decide which drugs to fund. So what happens? A breakthrough drug gets approved but then sits on a shelf instead of helping the people who need it. That’s a distribution failure, plain and simple.

Public-Private Partnerships Can Reduce Costs by Up to 30%

There is some good news. One of the few things that’s actually working is public-private partnerships (PPPs) that focus on technology transfer and building local manufacturing. We’ve seen evidence from groups like the Medicines Patent Pool in sub-Saharan Africa showing these collaborations can cut the cost of essential drugs by up to 30%. That’s a huge drop. From my perspective, this is one of the only real long-term solutions on the table. Instead of just haggling over the price of imported drugs, these partnerships help LMICs to make their own. It means transferring the IP and technical know-how, and investing in actual factories on the ground. When you decentralize manufacturing and build up regional hubs, countries aren’t as dependent on foreign suppliers, they’re less exposed to supply chain shocks, and their costs go way down. It also builds up the local economy with skilled jobs. Sure, these partnerships are a headache to set up and run, but the payoff in affordability and health security is massive. It’s the difference between a handout and building real, sustainable capacity.

Challenging the Conventional Wisdom: The “Cost of Innovation” Argument

We always hear the same defense for high drug prices: it’s the unavoidable “cost of innovation.” The industry points to massive R&D spending and the high failure rate of clinical trials to justify their pricing, claiming that without huge profits, innovation would dry up. And while I don’t deny that drug development is expensive, that argument is a massive oversimplification that conveniently ignores other models. This isn’t a situation where lower prices automatically kill off all future innovation.

For starters, those R&D cost figures are often inflated, and the argument usually leaves out how much of the foundational science was funded by taxpayers through university grants and public research. The laser focus on blockbuster drugs for rich markets also means innovation follows the money, not the global health need. We have to ask if the ‘cost of innovation’ model is actually giving us the best medicines for the planet’s health, or just the most profitable ones for a handful of wealthy markets. There are other ways to do this. Things like prize funds for NTD research or public buyouts of patents could separate the R&D incentive from the final sales price, giving us the drugs we need without the outrageous price tags. The industry story says there’s only one way to innovate, but that’s just not true.

Fixing the mess of market access and pricing for WHO-listed drugs means we have to stop tinkering with the broken models we already have. If we want life-saving treatments to actually reach everyone who needs them, we have to get serious about sustainable local manufacturing and force some transparency into pricing.